x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012559
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic phospho-peptide corresponding to residues surrounding Ser177 of human optineurin protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | OPTN |
| UniProt No. | Q96CV9 |
| Gene ID | 10133 |
| Gene Description | Optineurin is a signaling protein involved in maintenance of the Golgi complex, membrane trafficking, NF-κB, and interferon signaling. Mutations in the gene encoding optineurin have been associated with human diseases including glaucoma, Paget disease of bone, and amyotrophic lateral sclerosis. Optineurin is thought to contribute to these pathologies through regulation of inflammatory signaling, autophagy, and mitophagy. The NF-κB-activating kinase/TANK-binding kinase 1 phosphorylates optineurin at serine 177, regulating optineurin’s role in autophagy and mitophagy. The tumor suppressor HACE1 ubiquitylates optineurin, promoting the interaction of optineurin with the autophagy receptor p62/SQSTM1.Phosphorylation of optineurin at serine 177 by TBK1 enhances binding to LC3 and promotes autophagic clearance. Additional studies also suggest that serine 177 is phosphorylated during mitosis by PLK1. In addition to serine 177, TBK1 also phosphorylates optineurin at serine 473 and 513, which can enhance its binding to ubiquitin chains and promote mitophagy. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
